Impact of zoledronic acid on control of metastatic spinal cord compression

D. Rades, S. G. Hakim, A. Bajrovic, J. H. Karstens, T. Veninga, V. Rudat, S. E. Schild

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background. Zoledronic acid was demonstrated to reduce the rate of skeletal-related events, a hypernym including various outcomes, in patients with bone metastases. In contrast to other studies, this matched-pair analysis focused solely on the impact of zoledronic acid on metastatic spinal cord compression (MSCC).Patients and methods. Data from 98 patients with MSCC receiving radiotherapy plus zoledronic acid were matched 1:2 to 196 patients receiving radiotherapy alone for ten potential prognostic factors. Both groups were compared for local control of MSCC within the irradiated region, overall control of MSCC (local and distant MSCC control), and survival.Results. The 1-year local control rates were 90% after radiotherapy plus zoledronic acid and 81%, after radiotherapy alone (p=0.042). The 1-year overall control rates were 87% and 75%, respectively (p =0.016), and the 1-year survival rates were 60% and 52%, respectively (p=0.17). Results were significant in the Cox proportional hazards model regarding local control (p=0.024) and overall control (p =0.008).Conclusion. According to the results of this study, zoledronic acid was associated with improved control of MSCC in irradiated patients.

Original languageEnglish (US)
Pages (from-to)910-916
Number of pages7
JournalStrahlentherapie und Onkologie
Volume188
Issue number10
DOIs
StatePublished - Oct 2012

Fingerprint

zoledronic acid
Spinal Cord Compression
Radiotherapy
Matched-Pair Analysis
Proportional Hazards Models
Survival Rate

Keywords

  • Local control
  • Metastatic spinal cord compression
  • Radiotherapy
  • Treatment outcomes
  • Zoledronic acid

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Oncology

Cite this

Rades, D., Hakim, S. G., Bajrovic, A., Karstens, J. H., Veninga, T., Rudat, V., & Schild, S. E. (2012). Impact of zoledronic acid on control of metastatic spinal cord compression. Strahlentherapie und Onkologie, 188(10), 910-916. https://doi.org/10.1007/s00066-012-0158-4

Impact of zoledronic acid on control of metastatic spinal cord compression. / Rades, D.; Hakim, S. G.; Bajrovic, A.; Karstens, J. H.; Veninga, T.; Rudat, V.; Schild, S. E.

In: Strahlentherapie und Onkologie, Vol. 188, No. 10, 10.2012, p. 910-916.

Research output: Contribution to journalArticle

Rades, D, Hakim, SG, Bajrovic, A, Karstens, JH, Veninga, T, Rudat, V & Schild, SE 2012, 'Impact of zoledronic acid on control of metastatic spinal cord compression', Strahlentherapie und Onkologie, vol. 188, no. 10, pp. 910-916. https://doi.org/10.1007/s00066-012-0158-4
Rades D, Hakim SG, Bajrovic A, Karstens JH, Veninga T, Rudat V et al. Impact of zoledronic acid on control of metastatic spinal cord compression. Strahlentherapie und Onkologie. 2012 Oct;188(10):910-916. https://doi.org/10.1007/s00066-012-0158-4
Rades, D. ; Hakim, S. G. ; Bajrovic, A. ; Karstens, J. H. ; Veninga, T. ; Rudat, V. ; Schild, S. E. / Impact of zoledronic acid on control of metastatic spinal cord compression. In: Strahlentherapie und Onkologie. 2012 ; Vol. 188, No. 10. pp. 910-916.
@article{51b6357c9ddf40d99e98bb9d392447dc,
title = "Impact of zoledronic acid on control of metastatic spinal cord compression",
abstract = "Background. Zoledronic acid was demonstrated to reduce the rate of skeletal-related events, a hypernym including various outcomes, in patients with bone metastases. In contrast to other studies, this matched-pair analysis focused solely on the impact of zoledronic acid on metastatic spinal cord compression (MSCC).Patients and methods. Data from 98 patients with MSCC receiving radiotherapy plus zoledronic acid were matched 1:2 to 196 patients receiving radiotherapy alone for ten potential prognostic factors. Both groups were compared for local control of MSCC within the irradiated region, overall control of MSCC (local and distant MSCC control), and survival.Results. The 1-year local control rates were 90{\%} after radiotherapy plus zoledronic acid and 81{\%}, after radiotherapy alone (p=0.042). The 1-year overall control rates were 87{\%} and 75{\%}, respectively (p =0.016), and the 1-year survival rates were 60{\%} and 52{\%}, respectively (p=0.17). Results were significant in the Cox proportional hazards model regarding local control (p=0.024) and overall control (p =0.008).Conclusion. According to the results of this study, zoledronic acid was associated with improved control of MSCC in irradiated patients.",
keywords = "Local control, Metastatic spinal cord compression, Radiotherapy, Treatment outcomes, Zoledronic acid",
author = "D. Rades and Hakim, {S. G.} and A. Bajrovic and Karstens, {J. H.} and T. Veninga and V. Rudat and Schild, {S. E.}",
year = "2012",
month = "10",
doi = "10.1007/s00066-012-0158-4",
language = "English (US)",
volume = "188",
pages = "910--916",
journal = "Strahlentherapie und Onkologie : Organ der Deutschen R{\"o}ntgengesellschaft ... [et al]",
issn = "0179-7158",
publisher = "Urban und Vogel",
number = "10",

}

TY - JOUR

T1 - Impact of zoledronic acid on control of metastatic spinal cord compression

AU - Rades, D.

AU - Hakim, S. G.

AU - Bajrovic, A.

AU - Karstens, J. H.

AU - Veninga, T.

AU - Rudat, V.

AU - Schild, S. E.

PY - 2012/10

Y1 - 2012/10

N2 - Background. Zoledronic acid was demonstrated to reduce the rate of skeletal-related events, a hypernym including various outcomes, in patients with bone metastases. In contrast to other studies, this matched-pair analysis focused solely on the impact of zoledronic acid on metastatic spinal cord compression (MSCC).Patients and methods. Data from 98 patients with MSCC receiving radiotherapy plus zoledronic acid were matched 1:2 to 196 patients receiving radiotherapy alone for ten potential prognostic factors. Both groups were compared for local control of MSCC within the irradiated region, overall control of MSCC (local and distant MSCC control), and survival.Results. The 1-year local control rates were 90% after radiotherapy plus zoledronic acid and 81%, after radiotherapy alone (p=0.042). The 1-year overall control rates were 87% and 75%, respectively (p =0.016), and the 1-year survival rates were 60% and 52%, respectively (p=0.17). Results were significant in the Cox proportional hazards model regarding local control (p=0.024) and overall control (p =0.008).Conclusion. According to the results of this study, zoledronic acid was associated with improved control of MSCC in irradiated patients.

AB - Background. Zoledronic acid was demonstrated to reduce the rate of skeletal-related events, a hypernym including various outcomes, in patients with bone metastases. In contrast to other studies, this matched-pair analysis focused solely on the impact of zoledronic acid on metastatic spinal cord compression (MSCC).Patients and methods. Data from 98 patients with MSCC receiving radiotherapy plus zoledronic acid were matched 1:2 to 196 patients receiving radiotherapy alone for ten potential prognostic factors. Both groups were compared for local control of MSCC within the irradiated region, overall control of MSCC (local and distant MSCC control), and survival.Results. The 1-year local control rates were 90% after radiotherapy plus zoledronic acid and 81%, after radiotherapy alone (p=0.042). The 1-year overall control rates were 87% and 75%, respectively (p =0.016), and the 1-year survival rates were 60% and 52%, respectively (p=0.17). Results were significant in the Cox proportional hazards model regarding local control (p=0.024) and overall control (p =0.008).Conclusion. According to the results of this study, zoledronic acid was associated with improved control of MSCC in irradiated patients.

KW - Local control

KW - Metastatic spinal cord compression

KW - Radiotherapy

KW - Treatment outcomes

KW - Zoledronic acid

UR - http://www.scopus.com/inward/record.url?scp=84866709172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866709172&partnerID=8YFLogxK

U2 - 10.1007/s00066-012-0158-4

DO - 10.1007/s00066-012-0158-4

M3 - Article

C2 - 22903395

AN - SCOPUS:84866709172

VL - 188

SP - 910

EP - 916

JO - Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]

JF - Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]

SN - 0179-7158

IS - 10

ER -